As filed with the Securities and Exchange Commission on December 11, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NewAmsterdam Pharma Company N.V.
(Exact Name of Registrant as Specified in Its Charter)
| The Netherlands | Not Applicable | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
Gooimeer 2-35
1411 DC Naarden
The Netherlands
Tel: +31 (0) 35 206 2971
(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)
NewAmsterdam Pharma Corporation
20803 Biscayne Blvd, Suite #105
Aventura, FL 33180
Tel: +31 (0) 35 206 2971
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies of all communications, including communications sent to agent for service, should be sent to:
Brian K. Rosenzweig
Kerry S. Burke
Covington & Burling LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
Tel: (212) 841-1000
Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.
If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-280687
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐
If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☒ | |||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
This registration statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, NewAmsterdam Pharma Company N.V. (the “Registrant”), is filing this Registration Statement on Form S-3 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-3 (File No. 333-280687) (the “Prior Registration Statement”), which the Registrant filed with the Commission on July 3, 2024 and which the Commission declared effective on July 12, 2024.
The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate amount of securities registered for issuance by the Registrant by a proposed additional aggregate offering price of $78,975,000, which includes shares that may be sold by the Registrant in the event the underwriters exercise their option to purchase additional ordinary shares of the Registrant. The additional securities that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price of unsold securities under the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.
The required opinions and consents are listed on an Exhibit Index below and filed herewith or incorporated by reference herein.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16. Exhibits
The following documents are filed as part of this registration statement on Form S-3:
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Naarden, the Netherlands, on December 11, 2024.
| NewAmsterdam Pharma Company N.V. | ||||
| By: | /s/ Michael Davidson | |||
| Name: | Dr. Michael Davidson | |||
| Title: | Chief Executive Officer and Executive Director | |||
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
| Name | Title | Date | ||
| /s/ Michael Davidson |
Chief Executive Officer and Executive Director | December 11, 2024 | ||
| Dr. Michael Davidson | (Principal Executive Officer) | |||
| /s/ Ian Somaiya |
Chief Financial Officer | December 11, 2024 | ||
| Ian Somaiya | (Principal Financial Officer) | |||
| * |
Chief Accounting Officer | December 11, 2024 | ||
| Louise Kooij | (Principal Accounting Officer) | |||
| * |
Chairperson and Non-Executive Director | December 11, 2024 | ||
| William H. Lewis | ||||
| * |
Chief Scientific Officer and Non-Executive Director | December 11, 2024 | ||
| Dr. John Kastelein | ||||
| /s/ Wouter Joustra |
Non-Executive Director | December 11, 2024 | ||
| Wouter Joustra | ||||
| * |
Non-Executive Director | December 11, 2024 | ||
| Dr. Nicholas Downing | ||||
| * |
Non-Executive Director | December 11, 2024 | ||
| Dr. James N. Topper | ||||
| * |
Non-Executive Director | December 11, 2024 | ||
| Dr. Louis Lange | ||||
| * |
Non-Executive Director | December 11, 2024 | ||
| John W. Smither | ||||
| * |
Non-Executive Director | December 11, 2024 | ||
| Janneke van der Kamp | ||||
| /s/ Mark C. McKenna |
Non-Executive Director | December 11, 2024 | ||
| Mark C. McKenna | ||||
| *By: | /s/ Michael Davidson | |
| Dr. Michael Davidson | ||
| Attorney-in-Fact |
AUTHORIZED REPRESENTATIVE
Pursuant to the requirement of the Securities Act, the undersigned, the duly undersigned representative in the United States of NewAmsterdam Pharma Company N.V., has signed this registration statement in the United States, on December 11, 2024.
| NewAmsterdam Pharma Corporation | ||
| By: | /s/ Michael Davidson | |
| Name: Dr. Michael Davidson | ||
| Title: President | ||